Pharmacology of the biological response modifier bropirimine (PNU-54461) on experimental autoimmune encephalomyelitis (EAE) in mice.
In murine severe experimental autoimmune encephalomyelitis (EAE), an animal model for the human disease multiple sclerosis (MS), we tested the efficacy of a 5-halo-6-phenyl pyrimidinone compound, bropirimine (PNU-54461). We observed that the compound is active in suppressing EAE when administered orally, a significant pharmacological advantage compared to some current therapies for the treatment of MS. Furthermore, bropirimine was most efficacious when dosing was begun 5-10 days after injection of myelin basic protein, the protein isolated from the central nervous system and used for inducing EAE in our model. This is a period of time following the initial immunological events leading to the disease, when large-scale leukocyte infiltration into the central nervous system begins. Following oral dosing, bropirimine peaked in the blood within 3 h and was cleared to undetectable concentrations within 16-18 h. Despite the pharmacokinetics in the blood, bropirimine was fully efficacious when dosed orally every two or three days. Surprisingly, bropirimine treatment did not result in a statistically significant decrease in leukocyte infiltration into the lower spinal cord, unless the compound was dosed daily at a high concentration. We also observed the concentration and time course of alpha-interferon in blood following oral dosing of bropirimine. The kinetics of interferon in the blood are similar to, but clearly distinguishable from, the pharmacokinetics of bropirimine in the blood. It is not clear whether or not the induction of interferon plays a key role in the efficacy of bropirimine. Nevertheless, the results using bropirimine in EAE suggest that the compound may be useful for the treatment of multiple sclerosis.
Vroegop
S M
SM
Discovery Technologies, Pharmacia & Upjohn Inc, Kalamazoo, MI 49007-4940, USA. stephen.e.buxser@am.pnu.com
Chapman
D L
DL
Galinet
L A
LA
Decker
D E
DE
Ready
K A
KA
Brideau
R J
RJ
Dunn
C J
CJ
Buxser
S E
SE
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D003596:Cytosine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000517:prevention & control*; D005260:Female; D006912:Hydroxyquinolines / Q000494:pharmacology; D007150:Immunohistochemistry; D007372:Interferons / Q000097:blood; D051379:Mice; D009103:Multiple Sclerosis / Q000188:drug therapy
D000276:Adjuvants, Immunologic; D006912:Hydroxyquinolines; C045282:roquinimex; D003596:Cytosine; D007372:Interferons; C033560:bropirimine